{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:00:10Z","timestamp":1761512410097},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1007\/s11938-003-0048-z","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T15:13:20Z","timestamp":1180883600000},"page":"465-472","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of hepatocellular carcinoma"],"prefix":"10.1007","volume":"6","author":[{"given":"Jonathan M.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","volume":"349","author":"CJ Murray","year":"1997","unstructured":"Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269\u20131276.","journal-title":"Lancet"},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007117","volume":"19","author":"FX Bosch","year":"1999","unstructured":"Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271\u2013285.","journal-title":"Semin Liver Dis"},{"key":"48_CR3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745\u2013750.","journal-title":"N Engl J Med"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.510270140","volume":"27","author":"J Collier","year":"1998","unstructured":"Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998, 27:273\u2013278.","journal-title":"Hepatology"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Lllovet","year":"1999","unstructured":"Lllovet JM, Bustamante J, Castells A, et al.: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62\u201367.","journal-title":"Hepatology"},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","volume":"31","author":"The Cancer of the Liver Italian Program (CLIP) Investigators","year":"2000","unstructured":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31:840\u2013845.","journal-title":"Hepatology"},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329\u2013338.","journal-title":"Semin Liver Dis"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","volume":"111","author":"J Bruix","year":"1996","unstructured":"Bruix J, Castells A, Bosch J, et al.: Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996, 111:1018\u20131022.","journal-title":"Gastroenterology"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/bjs.1800780423","volume":"78","author":"KJ Paquet","year":"1991","unstructured":"Paquet KJ, Koussouris P, Mercado MA, et al.: Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991, 78:459\u2013462.","journal-title":"Br J Surg"},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00000658-199804000-00013","volume":"227","author":"CM Lo","year":"1998","unstructured":"Lo CM, Lai EC, Liu CL, et al.: Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998, 227:527\u2013532.","journal-title":"Ann Surg"},{"key":"48_CR11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/hep.510280511","volume":"28","author":"T Takayama","year":"1998","unstructured":"Takayama T, Makuuchi M, Hirohashi S, et al.: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998, 28:1241\u20131246.","journal-title":"Hepatology"},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1470-2045(02)00873-2","volume":"3","author":"JD Schwartz","year":"2002","unstructured":"Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002, 3:593\u2013603.","journal-title":"Lancet Oncol"},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(98)06475-7","volume":"353","author":"WY Lau","year":"1999","unstructured":"Lau WY, Leung TW, Ho SK, et al.: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353:797\u2013801.","journal-title":"Lancet"},{"key":"48_CR14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199606133342402","volume":"334","author":"Y Muto","year":"1996","unstructured":"Muto Y, Moriwaki H, Ninomiya M, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561\u20131567.","journal-title":"N Engl J Med"},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-198804000-00002","volume":"207","author":"JG O\u2019Grady","year":"1988","unstructured":"O\u2019Grady JG, Polson RJ, Rolles K, et al.: Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988, 207:373\u2013379.","journal-title":"Ann Surg"},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/hep.510270616","volume":"27","author":"JM Llovet","year":"1998","unstructured":"Llovet JM, Bruix J, Fuster J, et al.: Liver transplantation for small hepatocellular carcinoma: the tumornode-metastasis classification does not have prognostic power. Hepatology 1998, 27:1572\u20131577.","journal-title":"Hepatology"},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrohosis. N Engl J Med 1996, 334:693\u2013699.","journal-title":"N Engl J Med"},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, et al.: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394\u20131403. The study showed good outcomes among patients with larger tumors; however, the analysis is based on explant pathology. It is reasonable to apply expanded criteria if a live donor is available, but may not apply if there is a prolonged wait for transplant.","journal-title":"Hepatology"},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1053\/he.2000.5763","volume":"31","author":"PE Majno","year":"2000","unstructured":"Majno PE, Sarasin FP, Mentha G, Hadengue A: Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000, 31:899\u2013906.","journal-title":"Hepatology"},{"key":"48_CR20","first-page":"97","volume":"3","author":"K Okuda","year":"1998","unstructured":"Okuda K: Intratumor ethanol injection. J Surg Oncol 1998, 3(suppl):97\u201399.","journal-title":"J Surg Oncol"},{"key":"48_CR21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1148\/radiology.197.1.7568806","volume":"197","author":"T Livraghi","year":"1995","unstructured":"Livraghi T, Giorgio A, Marin G: Hepatocellular carcinoma and cirrhosis in 746 patients: long term results of percutaneous ethanol injection. Radiology 1995, 197:101\u2013108.","journal-title":"Radiology"},{"key":"48_CR22","first-page":"1121","volume":"18","author":"A Castells","year":"1993","unstructured":"Castells A, Bruix J, Bru C, et al.: Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993, 18:1121\u20131126.","journal-title":"Hepatology"},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1148\/radiology.210.3.r99fe40655","volume":"210","author":"T Livraghi","year":"1999","unstructured":"Livraghi T, Goldberg SN, Lazzaroni S, et al.: Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999, 210:655\u2013661.","journal-title":"Radiology"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiology.214.3.r00mr02761","volume":"214","author":"T Livraghi","year":"2000","unstructured":"Livraghi T, Goldberg SN, Lazzaroni S, et al.: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000, 214:761\u2013768.","journal-title":"Radiology"},{"key":"48_CR25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1053\/jhep.2001.24233","volume":"33","author":"JM Llovet","year":"2001","unstructured":"Llovet JM, Vilana R, Bru C, et al.: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001, 33:1124\u20131129.","journal-title":"Hepatology"},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734\u20131739. Well-designed trial showing benefit of chemoembolization in selected patients with advanced HCC.","journal-title":"Lancet"},{"key":"48_CR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429\u2013442.","journal-title":"Hepatology"},{"key":"48_CR28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0016-5085(95)90402-6","volume":"109","author":"A Castells","year":"1995","unstructured":"Castells A, Bruix J, Bru C, et al.: Treatment of hepatocellular carcinoma with tamoxifen: a doubleblind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109:917\u2013922.","journal-title":"Gastroenterology"},{"key":"48_CR29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","volume":"42","author":"E Kouroumalis","year":"1998","unstructured":"Kouroumalis E, Skordilis P, Thermos K, et al.: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42:442\u2013447.","journal-title":"Gut"},{"key":"48_CR30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/jhep.2002.35071","volume":"36","author":"MF Yuen","year":"2002","unstructured":"Yuen MF, Poon RT, Lai CL, et al.: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36:687\u2013691.","journal-title":"Hepatology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-003-0048-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0048-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:59Z","timestamp":1559422619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-003-0048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s11938-003-0048-z","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}